Blood eosinophil count in the general population: typical values and potential confounders


This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online.

Copyright ©ERS 2020
BLOOD EOSINOPHIL COUNT IN THE GENERAL POPULATION:
TYPICAL VALUES AND POTENTIAL CONFOUNDERS

S Hartl¹,⁴, MK Breyer², OC Burghuber²,⁴, A Ofenheimer⁴, A Schrott¹, MH Urban², A Agusti⁵, M Studnicka⁶, EFM Wouters⁷ and R Breyer-Kohansal¹

¹Second Department of Respiratory and Critical Care Medicine and Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology, Otto Wagner Hospital, Vienna, Austria
²First Department of Respiratory Medicine and Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology, Otto Wagner Hospital, Vienna, Austria
⁴Sigmund Freud Medical University, Vienna, Austria
⁵Respiratory Institute, Hospital Clinic, IDIBAPS, University of Barcelona and National Spanish Network for Respiratory Research (CIBERES), Barcelona, Spain
⁶Department of Respiratory Medicine, Paracelsus Medical University, Salzburg, Austria
⁷Department of Respiratory Medicine, MUMC, Maastricht University, Maastricht, the Netherlands

Corresponding author: S Hartl, MD, MBA. Second Department for Respiratory and Critical Care Medicine and Ludwig Boltzmann Institute for COPD and Respiratory Epidemiology Otto Wagner Hospital | Sanatoriumstrasse 2 | 1140 Wien 1 Austria. E-mail: hartlsylvia@icloud.com.
Supported by the Municipal Department of Health and Environment of Vienna, the Federal State Governmental Department of Health of Lower Austria, the Ludwig Boltzmann Society, unrestricted scientific grants from Glaxo Smith Kline, Novartis Pharma, AstraZeneca, Chiesi Farmaceutici SpA, Menarini Pharma, Teva, MSD, Air Liquide Health Care, Pfizer, Boehringer Ingelheim. None of the supporting parties has any participation in the data, nor have they contributed to the design or the content of the manuscript.

Take-home message: The level of circulating blood eosinophils in healthy subjects is much lower than currently considered, is age dependant until 18 years, is higher in males and is influenced by several multimorbid conditions and lifestyle factors.

ABSTRACT

There is growing interest in blood eosinophil counts in the management of chronic respiratory conditions such as asthma and chronic obstructive pulmonary disease [COPD]). Despite this, typical blood eosinophil levels in the general population, and the impact of potential confounders on these levels have not been clearly defined.

We measured blood eosinophil counts in a random sample of 11,042 subjects recruited from the general population in Austria. We then: (1) identified factors associated with high blood eosinophil counts (>75th percentile); and, (2) excluded subjects with these factors to estimate median blood eosinophil counts in a ‘healthy’ sub-population (n=3641).

We found that: (1) in the entire cohort, age ≤18 years (odds ratio [OR] 2.41),
asthma (OR 2.05), current smoking (OR 1.72), positive skin prick test (OR 1.64), COPD (OR 1.56), metabolic syndrome (OR 1.41), male sex (OR 1.36) and obesity (OR 1.16) were significantly (p<0.05) associated with high blood eosinophil counts (binary multivariable logistic regression analysis); and had an additive effect; (2) after excluding these factors, in those older than 18 years, blood eosinophil counts were higher in males than in females (median 120 [5%-95% CI: 30–330] vs 100 [30-310] cells/µL, respectively) and did not change with age.

Median blood eosinophil counts in adults are considerably lower than those currently regarded as normal, do not change with age beyond puberty, but are significantly influenced by a variety of factors which have an additive effect. These observations will contribute to the interpretation of blood eosinophil levels in clinical practice.

INTRODUCTION

The Global Initiative for Asthma (GINA) recommends the use of blood eosinophil counts to identify patients with Type II inflammation, and to target the use of biologics for the management of severe asthma [1]. Type II inflammation is mainly triggered by allergy, and causes 50% of asthma manifestations [2-4]. Moreover, excluding persons with allergic sensitisation measured by positive skin prick test reduced the overall average blood eosinophil count in an early study by Felarca and Lowell, underlining the important relationship between allergy and blood eosinophils [5].

More recently, the Global Strategy for the Diagnosis, Management
and Prevention of Chronic Obstructive Lung Disease (GOLD) recommends the use of circulating eosinophils to guide therapy with inhaled corticosteroids (ICS) in patients with stable chronic obstructive pulmonary disease (COPD) who continue to exacerbate despite appropriate bronchodilator therapy [6, 7]. According to GOLD, a blood eosinophil count threshold of 300 cells/μL can be used to identify patients that are most likely to benefit from treatment with ICS [6]. The blood eosinophil thresholds that these documents use are often criticised because they are believed to be within the normal eosinophil range [5, 8]. However, the typical range of blood eosinophil counts in the general population is not well established, since the role of potential confounding factors other than atopy [2, 5], such as age, sex, environmental exposures [3, 9, 10] or presence of disease [4, 11-15] is unclear.

To address these gaps, we measured blood eosinophil counts in a large (n=11,423), representative, and carefully characterised cohort of individuals living in Austria, who were recruited from the general population and stratified by age, sex and residential area (urban/rural). In these individuals, we aimed to: (1) identify factors associated with high blood eosinophil counts (which we a priori defined as >75th percentile); and, (2) estimated blood eosinophil counts in a ‘healthy’ sub-population that excluded the identified confounders.

**METHODS**

**Study design**

The LEAD (Lung, hEart, sociAl, boDy) study (ClinicalTrials.gov; NCT01727518)
is a longitudinal, observational, population-based Austrian cohort, the design and methodological details of which have been published elsewhere [16]. Briefly, LEAD aims to investigate the impact of genetic, environmental, social, developmental and ageing factors on respiratory health and associated comorbidities through life. Between 2011 and 2016 LEAD recruited 11,423 participants, aged 6 to 82 years, who will be followed-up every four years. The cross-sectional data gathered at recruitment was used for the current analysis. The Vienna Ethics Committee approved the study (EK-11-117-0711). All participants signed informed consent; for children below the age of 18 years, informed consent was signed by their parents or legal representative.

**Measurements**

The methods used in LEAD have been detailed elsewhere [16]. In brief, the following measurements were obtained in all participants at recruitment: (1) demographics (age, sex, height, weight, and body mass index [BMI]); (2) smoking status (never, former, current), with cumulative smoking exposure obtained by questionnaire (heavy smoking was defined as ≥20 pack-years); (3) blood pressure and electrocardiogram; (4) skin prick test; (5) forced spirometry, conducted according to international standards [17-19], with the diagnosis of asthma established following GINA recommendations and that of COPD on the basis of a post bronchodilator forced expiratory volume in 1 second to forced vital capacity ratio below the lower limit of normal in participants >40 years, with reference values derived from the Global Lung Function Initiative [20] (for the purpose of the current analyses, 79 participants with a diagnosis and symptoms of both asthma and COPD, were excluded); (6) cardiovascular disease
(hypertension, coronary artery disease, heart failure, atrial fibrillation), based on doctor’s diagnosis and validated by specific medication use; and, (7) fasting venous blood sample for standard blood chemistry (including blood glucose, haemoglobin A1c [HbA1c], cholesterol) and total and differential cell counts using a certified hospital laboratory. The diagnoses of diabetes (blood glucose ≥126 mg/dL, HbA1c ≥6.5% and/or medication), metabolic syndrome (central obesity plus at least two of: triglycerides ≥150 mg/dL or specific medication; high-density lipoprotein cholesterol <40 mg/dL in men, <50 mg/dL in women or specific medication; fasting glucose ≥100 mg/dL; systolic blood pressure ≥130 mmHg, or diastolic blood pressure ≥85 mmHg, or specific medication) and obesity (BMI >30 kg/m²) were established following international recommendations [21].

**Data analysis**

Results are presented as total counts (%), mean (standard deviation), median (interquartile range [IQR]) or geometric mean (95% confidence intervals), as appropriate. Normality of data was tested via Kolmogorov-Smirnov Test. The Mann-Whitney-U-Test was used to compare medians, and the Levene’s Test was used to compare IQRs. We used a forced entry binary multivariable logistic regression model (odds ratio [OR] and 95% CI) to investigate associations between ‘high’ blood eosinophil counts (>75th percentile) and potential confounders. The following covariates were included in the model: sex, age group, positive skin prick test, current smoking, former smoking, smoking history ≥20 pack-years (heavy smoking), obesity, metabolic syndrome,
cardiovascular disease (hypertension, coronary artery disease, heart failure, atrial fibrillation), diabetes, asthma, and COPD. All analyses were performed with SPSS Statistics for Windows, 2016 release (IBM Corp., VA, NY).

RESULTS

Characteristics of participants

Of the overall 11,423 participants in LEAD who completed lung function testing and the study questionnaires, 11,042 (96.7%) had blood eosinophil counts measured. Table 1 shows the main demographic characteristics of these 11,042 participants. Males and females were similarly represented; the mean (SD) age was 44.9 (19.3) years, spanning from 6 to 80 years. Atopy (positive skin prick test) was observed in 37.9% of participants, and 21.7% of individuals were current smokers, often heavy smokers (17.3%). Hypertension, obesity, and metabolic syndrome were identified in around 17% of the population studied, whereas COPD was diagnosed in 2.7% and asthma in 4.1% of participants. Cardiovascular diseases and diabetes occurred in 8.3% and 5.5% of individuals.

Blood eosinophil counts and potential confounders

Eosinophil counts ranged from 0 to 2020 cells/μL, and were non-normally distributed (Figure 1) with a right skewed shape (skewness 3.395, p<0.0001), so the geometric mean was calculated from log transformed data (128 cells/μL; Table 1). From these data, the 75th percentile (our
definition of ‘high eosinophil’) provided a cut-point of 210 cells/μL (Figure 1).

Figure 2 presents the results of the binary multivariable logistic regression model used to identify the factors that were significantly associated with high blood eosinophil counts. We found that male sex (OR 1.36 [95% CI 1.24–1.50]), younger age (≤18 years; 2.41 [2.01–2.89]), positive skin prick test (1.64 [1.50–1.80]), current smoking (1.72 [1.52–1.96]), obesity (1.16 [1.02–1.33]), presence of metabolic syndrome (1.41 [1.22–1.64]), and a diagnosis of asthma (2.05 [1.70–2.51]) or COPD (1.56 [1.20–2.03]) were all significantly associated with high blood eosinophil counts. By contrast, former smoking, hypertension, cardiovascular disease (myocardial infarction, atrial fibrillation, chronic heart failure) and diabetes were not. Of note, although current smoking was significantly associated with high blood eosinophil counts, high cumulative smoking exposure (≥20 pack years) was not (1.11 [0.96–1.27]). In a separate model, we checked for possible interactions between the covariates – there were none. However, atopy (positive skin prick test), current smoking and metabolic syndrome coexisted with increased mean blood eosinophil counts in the total study population (Figure 3a). The figure shows that individuals with atopy have higher blood eosinophil counts than those without atopy, as do current smokers compared to former/never smokers, and individuals with metabolic syndrome compared to those without the syndrome, demonstrating independent attributable risks for each single risk factor. In addition, the combination of atopy, current smoking and metabolic syndrome was associated with the highest blood eosinophil counts in
these subgroups. After excluding age and sex, of the remaining six
significantly associated factors that are potentially modifiable (positive skin
prick test, current smoking, obesity, presence of metabolic syndrome, and
a diagnosis of asthma or COPD), the presence of an increasing number of
concomitant associated factors was associated with higher blood
eosinophil counts (Figure 3b). Note that each individual could have a
maximum of five associated factors, given that those with both asthma
and COPD were excluding from these analyses.

Figure 4 shows the age and sex dependency of blood eosinophil counts
in the total LEAD cohort (top) and in the ‘healthy’ sub-population (bottom)
where all subjects with any of the factors identified by multivariable
logistic regression (Figure 2) were excluded – in other words, we
excluded individuals with a positive skin-prick test, who were current
smokers or were obese, or who had metabolic syndrome, COPD or
asthma. In both cases blood eosinophil counts were higher: (1) in early
life, plateauing after 18 years of age; (2) in males (blue) than females
(red); and, (3) in the total LEAD cohort (mean_{geom} 128 cells/µL) than in
the ‘healthy’ sub-population (mean_{geom} 107 cells/µL). The range (5%–
95%) of eosinophil counts in the ‘healthy’ adult sub-population was 30–
330 cells/µL in males and 30–310 cells/µL in females. Table 2 shows the
details of the range of blood eosinophil counts per age group and sex
(depicted in Figure 4) in the total population and the ‘healthy’ sub-
population.
DISCUSSION

This cross-sectional study in a large (n=11,042) and well-characterised general population cohort in Austria [16], provides several important and novel observations: (1) Blood eosinophil counts are highest in infancy and adolescence, and are independent of age after the age of 18 years, both in males and females; (2) eosinophil counts are higher in males than in females in all age groups; (3) a number of factors besides age and sex, including atopy, smoking, asthma, COPD, obesity and metabolic syndrome, are independently associated with high eosinophil counts, with these factors having an additive effect; (4) when these factors are excluded, circulating eosinophil levels in a healthy population aged 18 years and older is lower than that generally used in the clinic (median [5%–95% CI] 120 [30–330] cells/µL in males and 100 [30–310] cells/µL in females).

Previous studies

That blood eosinophil counts are higher both in children and atopic subjects was already known [22-26] and, in fact, our results provide further confirmatory evidence. Yet, we describe here other novel factors associated with high eosinophil counts, which likely help to explain the skewed distribution of blood eosinophil counts in the general population. Smoking is associated with exacerbations both in patients with asthma and those with COPD [23, 27-29], but the association with blood eosinophil counts in population cohorts has not been extensively studied. A recent analysis from the Copenhagen population cohort [30] showed
an increase in leucocytes but not in eosinophils in current smokers, whereas in a Japanese longitudinal cohort study, current smoking increased levels of white blood cells and eosinophils, with smoking cessation reducing levels to normal [10]. Moreover, an experimental study in young adults that measured blood eosinophils after smoking exposure and exercise showed a significant increase in blood eosinophil counts [31]. We hypothesise that exposure to tobacco smoke could activate different pathways of inflammation, resulting in increased blood eosinophil counts via innate lymphocytes such as in nonallergic asthma, or could result in neutrophilic inflammation associated with symptoms of bronchitis in smokers [29, 30]. As we did not find any association between C-reactive protein level and eosinophils (data not shown), it is unlikely that the increased level of blood eosinophils in our population is driven by common systemic inflammation. Furthermore, the few studies that have examined the relationship between eosinophil counts and obesity or metabolic syndrome have had contradictory results in general population cohorts [13, 32, 33], although one recent study showed that in metabolic syndrome blood eosinophil counts were increased in concordance with adipose tissue infiltration by eosinophils [34]. Our data highlight the complexity of the problem, given the associated factors had an independent, additive effect on blood eosinophil counts. To our knowledge this has not previously been demonstrated, and so warrants further attention when multimorbid patients are studied.

When all these factors were excluded in the ‘healthy’ sub-population, we observed that blood eosinophil counts were consistently higher in males
than females regardless of age and, importantly, that the median (and associated 95th percentile) eosinophil values in this ‘healthy’ population were lower than those regularly used in clinical practice. All in all, these observations will have to be considered in future studies that investigate the role of eosinophils in health and disease [35, 36].

**Implications for asthma and COPD management**

Several of this study’s observations may have direct implications for asthma management. First, we have to consider the age range of the investigated population, as our study shows that younger individuals have much higher blood eosinophil counts. Second, multimorbidity increases with age, both in patients with asthma and in the total population in our study. We hypothesise that the additive effect of factors associated with high eosinophil counts in our population cohort (metabolic syndrome, current smoking, obesity and atopy) could impact the predictive role of blood eosinophils for treatment efficacy in some subgroups of patients with asthma or COPD.

Our findings may also have implications for COPD management. First, the occurrence of COPD (like asthma) is, in itself, associated with increased blood eosinophil counts. Of note, the eosinophil counts of participants with COPD studied here are consistent with those reported in the Copenhagen general population study (median: 180 cells/µL [IQR 120–270]) [27] and in an analysis of the UK Clinical Practice Research Datalink (geometric mean: 192.2 cells/μL [95% CI: 190.2–194.1]) [37]. Second, eosinophil counts were independent of age and higher in males,
and COPD is most often diagnosed in males in their 6th or 7th decade of age. Third, a threshold of 300 cells/µL to support the use of ICS in patients with COPD is often questioned because it is believed to be within the ‘normal’ range of blood eosinophil counts [38]. Yet, our results suggest that average values, especially in those over the age of 40 years, are lower than this value, with medians of 100–120 cells/µL in the ‘healthy’ sub-population, with the 95th percentiles of these median values being between 290 and 350 cells/µL. In contrast, in patients with severe asthma (all of whom should already be receiving medium- or high-dose ICS) a blood eosinophil threshold of 300 cells/µL is suggested by GINA as suggesting eligibility for an anti-interleukin (IL) 5 or 5R, whereas a blood eosinophil threshold of 150 cells/µL or a fractional exhaled nitric oxide threshold of 25 ppb suggests eligibility for an anti-IL4Rα [1].

**Strengths and limitations**

The large sample size, age and sex stratification from the general population and careful consideration of potential confounders associated with high eosinophil counts are clear strengths of our study – as is that the recruited population is representative of the general Austrian population (as discussed in a previous manuscript on the objectives and external validity of the cohort [16]). That it was a cross-sectional analysis of an ongoing longitudinal study is a limitation. In particular, the results of the analyses do not provide any information on the use of blood eosinophil counts as a biomarker of, for example, response to therapy – which could be possible from a longitudinal study. Likewise, parasitic
infections are well known causes of high eosinophil levels and they were not specifically investigated (or excluded) from this analysis. However, the prevalence of parasitic infections in Austria is small (only 0.28% of samples in one study using data from 1990–2000 having positive results [39], and thus unlikely influence the current results. However, this factor may need to be considered in other regions of the world [24].

**Conclusions**

The results of this study define typical blood eosinophil counts in ‘healthy’ Austrian subjects and identify a number of factors associated with high eosinophil counts. The results clearly show that age and sex need more attention when defining ‘normal’ values, and that in complex comorbid situations blood eosinophil counts are higher with an increasing number of comorbidities. Overall, this novel information will contribute to better interpretation of blood eosinophil counts, both in general population cohorts and in patients with airway diseases.

**ACKNOWLEDGEMENTS**

Authors thank all participants for their willingness to contribute to medical research, and all field workers for their fantastic day to day work.
REFERENCES


18. Quanjer PH, Stanojevic S, Swanney MP, Miller MR. Recommendations for epidemiological studies on COPD. *The European respiratory journal* 2012:


TABLE LEGENDS

Table 1. Population baseline demographics, blood eosinophil counts and comorbidities.

Table 2: Blood eosinophil counts (median/range; cells/µL) in the total LEAD cohort and in a ‘healthy’ sub-population by age and sex. The ‘healthy’ sub-population excluded individuals with a positive skin prick test, who were current smokers, were obese, had metabolic syndrome, or had been diagnosed with asthma or COPD.

p1*: sex comparison (male vs female in age groups) via Mann-Whitney-U-Test;

p2‡: comparison of age group vs 6–<10 years via Mann-Whitney-U-Test.
FIGURE LEGENDS

Figure 1. Frequency distribution of blood eosinophil counts in the entire LEAD cohort. The black line indicates geometric mean (128 cells/µL) and the dotted line indicates the 75\textsuperscript{th} percentile (>201 cells/µL). For further explanations, see text.

Figure 2. Logistic multivariable regression analysis results (odds ratio [OR] and 95% confidence interval [CI]) for ‘high blood eosinophil’ (>210 cells/µL) in the LEAD cohort. Black symbols indicate significant OR (p<0.05); grey symbols denote non-significant associations. For further explanations, see text.

Figure 3a. Flow chart showing the coexistence of increased mean blood eosinophil counts and clinical characteristics. Sample sizes (n), geometric mean (SD)
Green boxes indicate no coexistence; orange boxes indicate coexistence of the characteristic and increased eosinophil counts; coloured frames indicate the characteristic (red: skin prick test+; orange: current smoking; yellow: metabolic syndrome).

Figure 3b. Cumulative effect on blood eosinophil counts of concomitant associated factors in the total population cohort. (n= sample size; boxes represent IQR: 25\textsuperscript{th} percentile–75\textsuperscript{th} percentile; black line = median; Whiskers show min-max values; bullets show extremes). The six factors included were positive skin prick test, current smoking, obesity, presence of metabolic syndrome, and a diagnosis of asthma or COPD. Note that
this analysis includes a maximum of five factors, since individuals with comorbid asthma and COPD were excluded from the analyses. For further explanations, see text.

**Figure 4.** Age and sex dependency of blood eosinophil counts in the total LEAD cohort (top) and the ‘healthy’ subpopulation (bottom). Lines represent median values and ribbons the range (5\textsuperscript{th} to 95\textsuperscript{th} percentile) for males (blue) and females (red). The ‘healthy’ sub-population excluded individuals with a positive skin prick test, who were current smokers, were obese, had metabolic syndrome, or had been diagnosed with asthma or COPD. For further explanations, see text.
<table>
<thead>
<tr>
<th>Variable</th>
<th>Odds ratio</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>6–18 years</td>
<td>2.41</td>
<td>(2.01–2.89)</td>
</tr>
<tr>
<td>asthma</td>
<td>2.05</td>
<td>(1.70–2.51)</td>
</tr>
<tr>
<td>smoking current</td>
<td>1.72</td>
<td>(1.52–1.96)</td>
</tr>
<tr>
<td>positive skin prick test</td>
<td>1.64</td>
<td>(1.50–1.80)</td>
</tr>
<tr>
<td>COPD</td>
<td>1.56</td>
<td>(1.20–2.03)</td>
</tr>
<tr>
<td>metabolic syndrome</td>
<td>1.41</td>
<td>(1.22–1.64)</td>
</tr>
<tr>
<td>male</td>
<td>1.36</td>
<td>(1.24–1.50)</td>
</tr>
<tr>
<td>obesity</td>
<td>1.16</td>
<td>(1.02–1.33)</td>
</tr>
<tr>
<td>&gt;18–&lt;60 years</td>
<td>1.14</td>
<td>(0.97–1.33)</td>
</tr>
<tr>
<td>cardiovascular disease</td>
<td>1.11</td>
<td>(0.93–1.34)</td>
</tr>
<tr>
<td>hypertension</td>
<td>1.10</td>
<td>(0.95–1.27)</td>
</tr>
<tr>
<td>heavy smokers</td>
<td>1.11</td>
<td>(0.96–1.27)</td>
</tr>
<tr>
<td>diabetes</td>
<td>1.09</td>
<td>(0.88–1.35)</td>
</tr>
<tr>
<td>40–&lt; 60 years</td>
<td>1.02</td>
<td>(0.89–1.16)</td>
</tr>
<tr>
<td>former smokers</td>
<td>0.98</td>
<td>(0.88–1.11)</td>
</tr>
</tbody>
</table>
Total sample
n=1042
Eosinophil absolute
blood count
geometric mean (SD):
128.1 (2.3) cells/µL.

SPT negative
n=6771
118.3 (2.4)

Former or never smoker
n=5263
113.3 (2.2)

Current smoker
n=1508
137.4 (2.3)

SPT positive
n=4135
145.5 (2.2)

Former or never smoker
n=3283
142.3 (2.3)

Current smoker
n=851
158.5 (2.2)

No metabolic syndrome
n=4278
109.7 (2.3)

Metabolic syndrome
n=985
130.4 (2.3)

No metabolic syndrome
n=1213
135.0 (2.3)

Metabolic syndrome
n=293
147.8 (2.4)

No metabolic syndrome
n=2864
139.6 (2.3)

Metabolic syndrome
n=419
162.2 (2.3)

No metabolic syndrome
n=733
155.8 (2.2)

Metabolic syndrome
n=118
176.4 (1.9)
total sample – age groups

healthy sample – age groups
<table>
<thead>
<tr>
<th>Demographics</th>
<th>LEAD participants (N=11,042)</th>
<th>Healthy sub-population (N=3641)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years), mean (SD) [range]</td>
<td>44.9 (19.3) [6–82]</td>
<td>41.8 (20.5) [6–82]</td>
</tr>
<tr>
<td>Age groups (years), n (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>6–18</td>
<td>1204 (10.9)</td>
<td>628 (17.2)</td>
</tr>
<tr>
<td>&gt;18–&lt;40</td>
<td>3155 (28.6)</td>
<td>1051 (28.9)</td>
</tr>
<tr>
<td>40–&lt;60</td>
<td>3787 (34.3)</td>
<td>1123 (30.8)</td>
</tr>
<tr>
<td>60–82</td>
<td>2896 (26.2)</td>
<td>839 (23.0)</td>
</tr>
<tr>
<td>Males, n (%)</td>
<td>5280 (47.8)</td>
<td>1524 (41.9)</td>
</tr>
<tr>
<td>Males aged 6–18 years</td>
<td>663 (55.1)</td>
<td>308 (49.0)</td>
</tr>
<tr>
<td>Males aged &gt;18–&lt;40 years</td>
<td>1510 (47.9)</td>
<td>404 (38.4)</td>
</tr>
<tr>
<td>Males aged 40–&lt;60 years</td>
<td>1727 (45.6)</td>
<td>432 (38.5)</td>
</tr>
<tr>
<td>Males aged 60–82 years</td>
<td>1375 (47.5)</td>
<td>380 (45.3)</td>
</tr>
<tr>
<td>BMI (kg/m(^2)), median [range] (25(^{th}); 75(^{th}) percentile)</td>
<td>24.8 [9.4–54.9] (21.7; 28.2)</td>
<td>23.2 [9.4–30.0] (20.6; 25.9)</td>
</tr>
<tr>
<td>Smoking history</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Never smokers, n (%)</td>
<td>5487 (49.7)</td>
<td>2424 (66.6)</td>
</tr>
<tr>
<td>Former smokers, n (%)</td>
<td>3159 (28.6)</td>
<td>1217 (33.4)</td>
</tr>
<tr>
<td>Current smokers, n (%)</td>
<td>2396 (21.7)</td>
<td>–</td>
</tr>
<tr>
<td>Heavy smokers (history ≥20 pack years), n (%)</td>
<td>1903 (17.3)</td>
<td>314 (8.6)</td>
</tr>
<tr>
<td>In former smokers</td>
<td>1055 (33.4) (N=3159)</td>
<td>314 (25.8) (N=1217)</td>
</tr>
<tr>
<td>In current smokers</td>
<td>848 (35.4) (N=2396)</td>
<td>–</td>
</tr>
<tr>
<td>Pack-years, mean (SD) [range]</td>
<td>18.8 (24.0) [0–275]</td>
<td>13.9 (16.6) [0–162]</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Positive skin prick test, n (%)</td>
<td>4135 (37.9)</td>
<td>–</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>1920 (17.4)</td>
<td>380 (10.4)</td>
</tr>
<tr>
<td>Obesity (BMI &gt;30 kg/m(^2)), n (%)</td>
<td>1877 (17.0)</td>
<td>–</td>
</tr>
<tr>
<td>Metabolic syndrome, n (%)</td>
<td>1849 (16.7)</td>
<td>–</td>
</tr>
<tr>
<td>Cardiovascular diseases, n (%)</td>
<td>916 (8.3)</td>
<td>222 (6.1)</td>
</tr>
<tr>
<td>Diabetes, n (%)</td>
<td>598 (5.5)</td>
<td>54 (1.5)</td>
</tr>
<tr>
<td>Asthma, n (%)</td>
<td>452 (4.1)</td>
<td>–</td>
</tr>
<tr>
<td>COPD, n (%)</td>
<td>301 (2.7)</td>
<td>–</td>
</tr>
<tr>
<td>Eosinophils</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Absolute count (cells/µL)</td>
<td>geometric mean (95% CI)</td>
<td></td>
</tr>
<tr>
<td>median (range)</td>
<td>128 (126–130)</td>
<td>107 (105–110)</td>
</tr>
<tr>
<td>5(^{th}); 25(^{th}); 75(^{th}); 95(^{th}) percentile</td>
<td>130 (0–2020)</td>
<td>110 (0–1820)</td>
</tr>
<tr>
<td>As % of total leucocytes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>mean (SD)</td>
<td>2.6 (2.0)</td>
<td>2.3 (1.9)</td>
</tr>
<tr>
<td>median (range)</td>
<td>2.0 (0.1–24.0)</td>
<td>1.8 (0.1–24.0)</td>
</tr>
<tr>
<td>5(^{th}); 25(^{th}); 75(^{th}); 95(^{th}) percentile</td>
<td>0.6; 1.3; 3.2; 6.3</td>
<td>0.5; 1.1; 2.8; 5.7</td>
</tr>
<tr>
<td>Absolute leucocyte count (cells/µL)</td>
<td>mean (SD)</td>
<td></td>
</tr>
<tr>
<td>median (range)</td>
<td>6.8 (1.9)</td>
<td>6.5 (1.7)</td>
</tr>
<tr>
<td>median (range)</td>
<td>6.5 (0–24.9)</td>
<td>6.2 (1.8–19.4)</td>
</tr>
<tr>
<td>5th; 25th; 75th; 95th percentile</td>
<td>LEAD participants (N=11,042)</td>
<td>Healthy sub-population (N=3641)</td>
</tr>
<tr>
<td>--------------------------------</td>
<td>-------------------------------</td>
<td>---------------------------------</td>
</tr>
<tr>
<td>4.3; 5.5; 7.8; 10.2</td>
<td>4.2; 5.3; 7.4; 9.5</td>
<td></td>
</tr>
<tr>
<td>Eosinophil count (cells/μL)</td>
<td>Sex</td>
<td>Age groups</td>
</tr>
<tr>
<td>---------------------------</td>
<td>-----</td>
<td>------------</td>
</tr>
<tr>
<td></td>
<td></td>
<td>6—&lt;10 years</td>
</tr>
<tr>
<td></td>
<td>n</td>
<td>Median (5th–95th percentile)</td>
</tr>
<tr>
<td></td>
<td>f</td>
<td>164</td>
</tr>
<tr>
<td></td>
<td>m</td>
<td>224</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p1: gender*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p2: age‡</td>
<td></td>
<td></td>
</tr>
<tr>
<td>'Healthy' sub-population</td>
<td>f</td>
<td>107</td>
</tr>
<tr>
<td></td>
<td>m</td>
<td>110</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>p1: gender*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>p2: age‡</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>